Online inquiry

IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11692MR)

This product GTTS-WQ11692MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets influenza B virus hemagglutinin gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NP_056660.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 956538
UniProt ID P03460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11692MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9099MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMCgp100
GTTS-WQ5273MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ12361MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ14468MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ12188MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ9092MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ5877MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ9929MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KB-004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW